New Senolytic Drugs Force Cancer's Zombie Cells to Self-Destruct
Scientists found drugs that kill senescent 'zombie cells' by blocking their key survival protein, shrinking tumors in mice.
20 articles
Scientists found drugs that kill senescent 'zombie cells' by blocking their key survival protein, shrinking tumors in mice.
New research reveals senescent cells have both harmful and protective roles, pushing anti-aging science toward targeted removal strategies.
A landmark study of 500 cat tumors reveals shared cancer-driving mutations with humans, pointing toward new breast cancer treatments.
Australian biotech company creates targeted treatment that attacks malignant plasma cells while sparing healthy ones in multiple myeloma patients.
USC researchers unlocked a scalable supply of engineered immune-cell precursors that fight tumors and may revolutionize cancer immunotherapy.
New biotech innovations are advancing prostate cancer therapy with promising approaches for better patient outcomes.
New compound AP503 activates GPR133 receptor to rebuild bone density in mice, offering hope for millions with osteoporosis.
First large-scale study reveals cats and humans share key cancer mutations, potentially leading to treatments for both species.
Researchers found 260,000 cancer-specific RNAs that act as molecular fingerprints and can be detected through simple blood tests.
New DoriVac platform uses folded DNA structures to trigger strong immune responses while being easier to manufacture and store than mRNA vaccines.
Researchers developed an AI system that identifies gene patterns predicting which cancers will spread, potentially transforming treatment decisions.
A new imaging breakthrough reveals how immune cells target cancer with nanoscale precision, opening doors for better immunotherapy.
When the DNA-repair gene EXO1 is overproduced, it damages DNA instead of fixing it—exposing a hidden vulnerability in multiple cancers.
Experimental PCAI compounds blocked over 90% of pancreatic cancer cell migration and triggered self-destruction by hyperactivating tumor growth pathways.
New research reveals how tumors reprogram neutrophils to produce CCL3, turning immune defenders into cancer allies.
A once-undruggable cancer driver has finally been targeted, cutting death risk by 60% in a landmark 500-patient trial.
Key biotech companies developing T cell engager therapies that redirect immune cells to fight cancer more effectively.
Redesigned immunotherapy injected into one tumor triggered complete cancer remission in 2 of 12 patients, with untreated tumors also disappearing.
Researchers identify N4BP2, the enzyme behind chromothripsis - a genetic catastrophe that helps one in four cancers rapidly evolve and resist treatment.
A protein called HOXD13 drives skin cancer growth and shields tumors from immune cells — disabling it could unlock powerful new treatments.